EA201792121A1 - Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao) - Google Patents

Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)

Info

Publication number
EA201792121A1
EA201792121A1 EA201792121A EA201792121A EA201792121A1 EA 201792121 A1 EA201792121 A1 EA 201792121A1 EA 201792121 A EA201792121 A EA 201792121A EA 201792121 A EA201792121 A EA 201792121A EA 201792121 A1 EA201792121 A1 EA 201792121A1
Authority
EA
Eurasian Patent Office
Prior art keywords
semicarbas
aminoxidase
ssao
inhibitor
sensitive
Prior art date
Application number
EA201792121A
Other languages
English (en)
Other versions
EA035668B1 (ru
Inventor
Эдвард Сейвори
Майкл Хиггинботтом
Original Assignee
Проксимэйджен Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проксимэйджен Лимитед filed Critical Проксимэйджен Лимитед
Publication of EA201792121A1 publication Critical patent/EA201792121A1/ru
Publication of EA035668B1 publication Critical patent/EA035668B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Описываются соли мезилат и сульфат (3S)-тетрагидрофуран-3-ил-(4S)-4-изопропил-1,4,6,7-тетрагидро-5H-имидазо[4,5-c]пиридин-5-карбоксилата, их гидраты и их применение в медицине.
EA201792121A 2015-04-24 2016-04-22 Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao) EA035668B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507031.1A GB201507031D0 (en) 2015-04-24 2015-04-24 New pharmaceutical salt forms
PCT/GB2016/051119 WO2016170351A1 (en) 2015-04-24 2016-04-22 Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Publications (2)

Publication Number Publication Date
EA201792121A1 true EA201792121A1 (ru) 2018-03-30
EA035668B1 EA035668B1 (ru) 2020-07-23

Family

ID=53488629

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792121A EA035668B1 (ru) 2015-04-24 2016-04-22 Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)

Country Status (20)

Country Link
US (1) US10316034B2 (ru)
EP (1) EP3286190B1 (ru)
JP (2) JP2018513189A (ru)
KR (1) KR20170139045A (ru)
CN (2) CN112851669A (ru)
AR (1) AR104360A1 (ru)
AU (1) AU2016251707B2 (ru)
BR (1) BR112017020016A2 (ru)
CA (1) CA2979144A1 (ru)
DK (1) DK3286190T3 (ru)
EA (1) EA035668B1 (ru)
ES (1) ES2804155T3 (ru)
GB (1) GB201507031D0 (ru)
HK (1) HK1249906A1 (ru)
HU (1) HUE049985T2 (ru)
IL (1) IL254153A0 (ru)
MX (1) MX2017013049A (ru)
PT (1) PT3286190T (ru)
SG (1) SG11201707867WA (ru)
WO (1) WO2016170351A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201618029D0 (en) 2016-10-25 2016-12-07 Proximagen Ltd New process
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) * 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU2002214505A1 (en) * 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
SE0004101D0 (sv) 2000-11-09 2000-11-09 Pharmacia Ab New use
WO2005082343A2 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US8633318B2 (en) * 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
MX2011002581A (es) * 2008-09-16 2011-04-07 Proximagen Ltd Compuestos nuevos i.
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
EP2755974A1 (en) * 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
EP3131539B1 (en) 2014-04-15 2018-12-05 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain

Also Published As

Publication number Publication date
ES2804155T3 (es) 2021-02-04
AU2016251707A1 (en) 2017-10-05
HUE049985T2 (hu) 2020-11-30
MX2017013049A (es) 2017-12-08
AU2016251707B2 (en) 2020-02-20
DK3286190T3 (da) 2020-07-13
EA035668B1 (ru) 2020-07-23
KR20170139045A (ko) 2017-12-18
US10316034B2 (en) 2019-06-11
JP2021073256A (ja) 2021-05-13
EP3286190B1 (en) 2020-06-03
HK1249906A1 (zh) 2018-11-16
CA2979144A1 (en) 2016-10-27
PT3286190T (pt) 2020-07-09
SG11201707867WA (en) 2017-11-29
CN112851669A (zh) 2021-05-28
WO2016170351A1 (en) 2016-10-27
IL254153A0 (en) 2017-10-31
AR104360A1 (es) 2017-07-12
JP2018513189A (ja) 2018-05-24
US20180111928A1 (en) 2018-04-26
CN107531702A (zh) 2018-01-02
EP3286190A1 (en) 2018-02-28
BR112017020016A2 (pt) 2018-06-19
GB201507031D0 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
AR103680A1 (es) Inhibidores selectivos de bace1
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201692436A1 (ru) Медицинское применение
CL2015002897A1 (es) Inhibidores de bace1
PH12016502353A1 (en) Pharmaceutical composition
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
EA201792123A1 (ru) Лечение боли
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
TW201613577A (en) Pharmaceutical combinations
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
EA201792121A1 (ru) Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM